Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Beasley

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Journal of Clinical Psychopharmacology|October 8, 1997
Fluoxetine in medically stable, depressed geriatric patients: effects on weightD J Goldstein, S H Hamilton, D N Masica, et al.
Clinical Pharmacokinetics|October 8, 1999
Olanzapine. Pharmacokinetic and pharmacodynamic profileJ T Callaghan, R F Bergstrom, L R Ptak, et al.
Clinical Therapeutics|December 16, 2000
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysisC M Beasley, S C Koke, M E Nilsson, et al.
American Journal of Public Health|September 11, 1992
Trend in suicide rates since fluoxetine introductionD N Masica, J G Kotsanos, C M Beasley, et al.
Biological Psychiatry|June 5, 1998
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophreniaG D Tollefson, T M Sanger, C M Beasley, et al.
Journal of Clinical Psychopharmacology|June 1, 1991
High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depressionC M Beasley, M E Sayler, J C Bosomworth, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 1996
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trialC M Beasley, G Tollefson, P Tran, et al.
Psychopharmacology|March 1, 1996
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trialC M Beasley, T Sanger, W Satterlee, et al.
The Journal of Clinical Psychiatry|April 18, 2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosisJ Czekalla, C M Beasley, M A Dellva, et al.
International Clinical Psychopharmacology|January 1, 1993
The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetineR F Bergstrom, C M Beasley, N B Levy, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Journal of Clinical Psychopharmacology|October 8, 1997
Fluoxetine in medically stable, depressed geriatric patients: effects on weightD J Goldstein, S H Hamilton, D N Masica, et al.
Clinical Pharmacokinetics|October 8, 1999
Olanzapine. Pharmacokinetic and pharmacodynamic profileJ T Callaghan, R F Bergstrom, L R Ptak, et al.
Clinical Therapeutics|December 16, 2000
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysisC M Beasley, S C Koke, M E Nilsson, et al.
American Journal of Public Health|September 11, 1992
Trend in suicide rates since fluoxetine introductionD N Masica, J G Kotsanos, C M Beasley, et al.
Biological Psychiatry|June 5, 1998
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophreniaG D Tollefson, T M Sanger, C M Beasley, et al.
Journal of Clinical Psychopharmacology|June 1, 1991
High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depressionC M Beasley, M E Sayler, J C Bosomworth, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 1996
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trialC M Beasley, G Tollefson, P Tran, et al.
Psychopharmacology|March 1, 1996
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trialC M Beasley, T Sanger, W Satterlee, et al.
The Journal of Clinical Psychiatry|April 18, 2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosisJ Czekalla, C M Beasley, M A Dellva, et al.
International Clinical Psychopharmacology|January 1, 1993
The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetineR F Bergstrom, C M Beasley, N B Levy, et al.
Pageof 6